News Major Progressive MS Trial Completes Enrollment For Experimental Therapy Major Progressive MS Trial Completes Enrollment For Experimental Therapy by Patricia Silva, PhD | May 13, 2015 Share this article: Share article via email Copy article link While multiple sclerosis (MS) is consideredĀ a rare condition with majorĀ unmet medical needs, the treatments for progressive forms of MS are evenĀ scarcer, with no viable, FDA-approved drugs available to specifically addressĀ these forms of the disease. Because of this, the MS community is eagerly followingĀ a major study led by the Cleveland Clinic Foundation to evaluate MN-166 (ibudilast), a novel treatment developed byĀ MediciNova, Inc. specifically to treat progressive MS. The investigators recently announced the completion of patient enrollment for the phase II clinical trial. The phase II study willĀ take place at 28 clinical sites in the United States and isĀ designed to evaluate the oral-inflammatory compound MN-166 in 250 patients who suffer from primary or secondary progressive MS. The trial’sĀ principal investigator isĀ Robert Fox, MD, MS, FAAN, aĀ neurologist from theĀ Mellen Center for Multiple Sclerosis at the Cleveland Clinic. Ibudilast works by inhibiting the phosphodiesterase enzyme, causing inflammation suppression. The agent has already been studied in a phase II trial involvingĀ 292 patients with relapsing MS and was foundĀ to decrease relapses. The study also revealed evidenceĀ that it could protectĀ the nervous system from damage caused by the disease. The product is already approved in both Japan and Korea for the treatment of cerebrovascular conditions and asthma, while it is also being studied in the U.S. for drug addiction. The study is being supported by MediciNova, as well as by an initiative from the National Institutes of Health (NIH), called the NeuroNEXT Network. In addition, the National MS Society has joined the project not only with financial support, but also by advocating among the MS community to increase clinical trial participation. [adrotate group=”4″] The organization believes that through this study, researchers may be able to both increase knowledge ofĀ the disease, as well as improve and accelerate treatment for patients with MS.Ā āThere is a significant, unmet need for treatments that can benefit people with progressive forms of MS,ā stated the chief research officer of the National MS Society, Timothy Coetzee, PhD in aĀ press release. āThis clinical trial of ibudilast will provide important information on a potential way to stop MS damage, as well as how to measure treatment benefits, and aligns well with the Societyās research agenda for stopping MS progression,ā added Coetzee. The trial is expected to last three years, including patient enrollment, treatment and data analyses. Data collection is scheduled to be completed by the end of next year. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags Ibudilast, MN-166, progressive multiple sclerosis
April 26, 2024 News by Margarida Maia, PhD Employment, income drop steadily over 2 decades after onset of MS
April 26, 2024 News by Marisa Wexler, MS Machine learning model predicts CIS to MS conversion risk: Study
April 25, 2024 Columns by Benjamin Hofmeister Finding safety while living with the constant threat of MS progression